Kedudukan dalam Saham
#36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Harga Saham
$0.30221445
Disegerakkan terakhir: 2023-05-22
Perubahan (1 hari)
-0.10%
Perubahan (1 tahun)
0.00%
Perdagangan Lysogene S.A. (LYS)
Harga LYS dengan permodalan pasaran b
Modal pasaran bagi Lysogene S.A.(LYS)
Modal Pasaran: $2.49M
Sehingga August 2026, Lysogene S.A. mempunyai modal pasaran sebanyak $2.49M. Ini menjadikan Lysogene S.A. syarikat ke-36618th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Lysogene S.A. dari 2017 hingga 2026
LYS berbanding dengan 5 teratas yang paling popular stocks
| Harga LYS |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+218,595,217.06%
|
|
|
|
|
$4.490T
|
+180,029,466.10%
|
|
|
|
|
$4.162T
|
+166,893,655.77%
|
|
|
|
|
$3.676T
|
+147,404,657.49%
|
|
|
|
|
$2.833T
|
+113,592,136.88%
|
